Melisa Carrasco1, Sanjai C Rao2, Cynthia F Bearer3, Sripriya Sundararajan4. 1. Department of Pediatrics, Children's Hospital, University of Maryland, Baltimore, Maryland. 2. Department of Neurology, University of Maryland, Baltimore, Maryland. 3. Division of Neonatology, Children's Hospital, University of Maryland, Baltimore, Maryland. 4. Division of Neonatology, Children's Hospital, University of Maryland, Baltimore, Maryland. Electronic address: ssundararajan@peds.umaryland.edu.
Abstract
INTRODUCTION: Gabapentin, an anticonvulsant, neuroleptic, and pain medication, is widely used in both adults and children for management of epilepsy, bipolar illness, and neuropathic pain. Gabapentin use has also been recommended for hyperemesis gravidarum and restless leg syndrome in pregnant mothers. OBJECTIVE: Although gabapentin use is deemed safe during pregnancy, no clinical reports of gabapentin withdrawal syndrome in a neonate have been described. RESULTS: We present a newborn who showed signs of withdrawal after prolonged in utero exposure to gabapentin. CLINICAL IMPLICATIONS: Clinicians should be aware of possible withdrawal symptoms from drugs such as gabapentin, administered to mothers during pregnancy. We also encourage the gradual tapering of gabapentin in neonates over weeks to months similar to the adult population.
INTRODUCTION:Gabapentin, an anticonvulsant, neuroleptic, and pain medication, is widely used in both adults and children for management of epilepsy, bipolar illness, and neuropathic pain. Gabapentin use has also been recommended for hyperemesis gravidarum and restless leg syndrome in pregnant mothers. OBJECTIVE: Although gabapentin use is deemed safe during pregnancy, no clinical reports of gabapentinwithdrawal syndrome in a neonate have been described. RESULTS: We present a newborn who showed signs of withdrawal after prolonged in utero exposure to gabapentin. CLINICAL IMPLICATIONS: Clinicians should be aware of possible withdrawal symptoms from drugs such as gabapentin, administered to mothers during pregnancy. We also encourage the gradual tapering of gabapentin in neonates over weeks to months similar to the adult population.
Authors: Hibo H Abdi; Nathalie L Maitre; Kristen L Benninger; Mark E Hester; Jonathan L Slaughter Journal: Pediatr Neurol Date: 2019-02-21 Impact factor: 3.372
Authors: Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori Journal: Drug Saf Date: 2016-10 Impact factor: 5.606
Authors: Lauren A Sanlorenzo; William O Cooper; Judith A Dudley; Shannon Stratton; Faouzi I Maalouf; Stephen W Patrick Journal: Hosp Pediatr Date: 2019-07-01
Authors: Evangelia Passia; Nathalie Rock; Riccardo E Pfister; Kuntheavy R Ing Lorenzini; Jules Desmeules; Caroline F Samer Journal: Front Pharmacol Date: 2017-04-21 Impact factor: 5.810
Authors: Krista F Huybrechts; Brian T Bateman; Rishi J Desai; Sonia Hernandez-Diaz; Kathryn Rough; Helen Mogun; Leslie S Kerzner; Jonathan M Davis; Megan Stover; Devan Bartels; Jennifer Cottral; Elisabetta Patorno Journal: BMJ Date: 2017-08-02